MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B
Status:
Completed
Trial end date:
2017-01-16
Target enrollment:
Participant gender:
Summary
Pharmacodynamic profiling will also be studied to characterize the effects of MMV390048 on P.
falciparum clearance kinetics in healthy subjects using the Induced Blood Stage Malaria
(IBSM) challenge model to determine the minimum inhibitory concentration of MMV390048 for P.
falciparum (Part B).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborators:
Clinical Network Services (CNS) Pty Ltd Q-Pharm Pty Limited QIMR Berghofer Medical Research Institute